Andrew A. Muskovitz

Dr. Andrew A. Muskovitz

Hematology | Oncology | Geriatrics
44344 Dequindre Road, Suite 260, 
Sterling Heights, MI 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
21 Years of Experience
44344 Dequindre Road, Suite 260, 
Sterling Heights, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrew Muskovitz is a Hematologist and an Oncologist in Sterling Heights, Michigan. Dr. Muskovitz has been practicing medicine for over 21 years and is rated as an Experienced provider by MediFind in the treatment of Intraductal Papilloma. His top areas of expertise are Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Thrombocytopenia, Bone Marrow Aspiration, and Ureteroscopy. Dr. Muskovitz is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Wayne State University School Of Medicine, 2005
Residency
University Of Illinois-Chicago Campus
Specialties
Hematology
Oncology
Geriatrics
Licenses
Internal Medicine in MI
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine
American Board Of Internal Medicine
American Board Of Internal Medicine
Fellowships
Karmanos Cancer Institute
University Of Illinois-Chicago Campus
Hospital Affiliations
Corewell Health Beaumont Troy Hospital
Corewell Health William Beaumont University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Cancer & Leukemia Center
44344 Dequindre Road, Suite 260, Sterling Heights, MI 48314
Other Locations
Cancer & Leukemia Center
53960 Van Dyke Avenue, Shelby Township, MI 48316

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: July 17, 2025
Intervention Type: Other, Drug
Study Drug: Naloxegol
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Enrollment Status: Available
Publish Date: September 23, 2024
Intervention Type: Drug
View 4 Less Clinical Trials

2 Total Publications

SWOG S1820: A pilot randomized trial of the Altering Intake, Managing Bowel Symptoms Intervention in Survivors of Rectal Cancer.
SWOG S1820: A pilot randomized trial of the Altering Intake, Managing Bowel Symptoms Intervention in Survivors of Rectal Cancer.
Journal: Cancer
Published: October 27, 2023
Similar Doctors
Howard R. Terebelo
Advanced in Intraductal Papilloma
Dr. Howard R. Terebelo
Oncology | Hematology | Hematology Oncology
Advanced in Intraductal Papilloma
Dr. Howard R. Terebelo
Oncology | Hematology | Hematology Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr, Suite 0331, 
Ann Arbor, MI 
 (40.1 miles away)
734-936-5738
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Howard Terebelo is an Oncologist and a Hematologist in Ann Arbor, Michigan. Dr. Terebelo is rated as a Distinguished provider by MediFind in the treatment of Intraductal Papilloma. His top areas of expertise are Multiple Myeloma, Essential Thrombocythemia, Familial Colorectal Cancer, Bone Marrow Aspiration, and Tissue Biopsy. Dr. Terebelo is currently accepting new patients.

Advanced in Intraductal Papilloma
Dr. Dawn M. Severson
Oncology | Hematology Oncology | Hematology
Advanced in Intraductal Papilloma
Dr. Dawn M. Severson
Oncology | Hematology Oncology | Hematology

Henry Ford Macomb Hospital Corporation

15855 19 Mile Rd, 
Clinton Township, MI 
 (6.6 miles away)
586-263-2300
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Dawn Severson is an Oncologist and a Hematologist Oncology provider in Clinton Township, Michigan. Dr. Severson is rated as a Distinguished provider by MediFind in the treatment of Intraductal Papilloma. Her top areas of expertise are Paget Disease of the Breast, Inflammatory Breast Cancer, Small Cell Lung Cancer (SCLC), and Lung Cancer. Dr. Severson is currently accepting new patients.

Advanced in Intraductal Papilloma
Dr. Michelene C. Liebman
Hematology Oncology | Hematology | Oncology
Advanced in Intraductal Papilloma
Dr. Michelene C. Liebman
Hematology Oncology | Hematology | Oncology
1 William Carls Dr, 
Commerce Township, MI 
 (20.9 miles away)
248-937-5045
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michelene Liebman is a Hematologist Oncology specialist and a Hematologist in Commerce Township, Michigan. Dr. Liebman is rated as a Distinguished provider by MediFind in the treatment of Intraductal Papilloma. Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, and Small Cell Lung Cancer (SCLC). Dr. Liebman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Muskovitz's expertise for a condition
ConditionClose
    View All 30 Distinguished Conditions
    View All 61 Advanced Conditions
    View All 133 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile